<p>Vincent LoPriore 通过其直接持股和关联实体披露了对 Hepion Pharmaceuticals, Inc. 的 21.46% 股权。该 13D 表格于 2026 年 5 月 1 日提交。该持股包括 Gravitas Capital LP 和 LoPriore 控制的 Invictus Capital Advisors 养老金计划所持有的股份。</p>
<p><strong>投资者意图</strong></p>
<p>LoPriore 持有 Hepion 股票是 &#34;出于投资目的&#34;，并且 &#34;可能会不时进一步收购普通股&#34;。他目前没有概述任何改变控制权、推动董事会变更或追求战略交易的计划。该文件描述了一种简单的投资立场，同时留有在条件允许时进行额外购买的空间。投资者可能会将此视为一个没有宣布议程的相当可观的内部对齐持股。</p>
<p><strong>投资者背景</strong></p>
<p>Vincent LoPriore 担任 Hepion Pharmaceuticals, Inc. 的执行董事长，并且是美国公民。他是 Gravitas Capital LP 的管理成员，以及 Invictus Capital Advisors 养老金计划的受托人和受益人。他有权投票和处置由 Gravitas Capital LP 和养老金计划持有的股份。</p>
<p>原始 SEC 文件: Hepion Pharmaceuticals, Inc. [ HEPA ] - SCHEDULE 13D -2026 年 5 月 1 日
<strong>免责声明</strong></p>
<p>这是一个由人工智能生成的摘要，可能包含不准确之处。请考虑与来源核实重要信息。请注意，此摘要仅基于提交给 SEC 的文件。</p>

HEPA

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普全球医疗股指数 ETF - iShares

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

<p>Vincent LoPriore 已披露在 Hepion Pharmaceuticals, Inc. 中持有 21.46% 的股份，该文件于 2026 年 5 月 1 日提交。该股份包括由 LoPriore 控制的 Gravitas Capital LP 和 Invictus Capital Advisors Pension Plan 的股份。他打算将这些股份用于投资目的，并可能在未来增持，但目前没有控制权变更或董事会调整的计划。LoPriore 是 Hepion 的执行董事长，并对这些股份拥有投票权</p>

<p>Vincent LoPriore disclosed a 21.46% stake in Hepion Pharmaceuticals, Inc. through his direct holdings and affiliated entities. The Schedule 13D was filed on May 1, 2026. The position combines shares held by Gravitas Capital LP and the Invictus Capital Advisors Pension Plan, which LoPriore controls.</p>
<div class="lb-trans"><p>Vincent LoPriore 通过其直接持股和关联实体披露了对 Hepion Pharmaceuticals, Inc. 的 21.46% 股权。该 13D 表格于 2026 年 5 月 1 日提交。该持股包括 Gravitas Capital LP 和 LoPriore 控制的 Invictus Capital Advisors 养老金计划所持有的股份。</p>
</div><p><strong>Investor Intent</strong></p>
<div class="lb-trans"><p><strong>投资者意图</strong></p>
</div><p>LoPriore holds Hepion shares &#34;for investment purposes&#34; and &#34;may make further acquisitions of the Common Stock from time to time.&#34; He does not outline any plans to change control, push for board changes, or pursue strategic transactions at this time. The filing describes a straightforward investment stance, while leaving room for additional buying if conditions warrant. Investors may read this as a sizable insider-aligned position without an announced agenda.</p>
<div class="lb-trans"><p>LoPriore 持有 Hepion 股票是 &#34;出于投资目的&#34;，并且 &#34;可能会不时进一步收购普通股&#34;。他目前没有概述任何改变控制权、推动董事会变更或追求战略交易的计划。该文件描述了一种简单的投资立场，同时留有在条件允许时进行额外购买的空间。投资者可能会将此视为一个没有宣布议程的相当可观的内部对齐持股。</p>
</div><p><strong>Investor's Background</strong></p>
<div class="lb-trans"><p><strong>投资者背景</strong></p>
</div><p>Vincent LoPriore serves as Executive Chairman of Hepion Pharmaceuticals, Inc. and is a U.S. citizen. He is the Managing Member of Gravitas Capital LP and the trustee and beneficiary of the Invictus Capital Advisors Pension Plan. He has the authority to vote and dispose of the shares held by Gravitas Capital LP and the pension plan.</p>
<div class="lb-trans"><p>Vincent LoPriore 担任 Hepion Pharmaceuticals, Inc. 的执行董事长，并且是美国公民。他是 Gravitas Capital LP 的管理成员，以及 Invictus Capital Advisors 养老金计划的受托人和受益人。他有权投票和处置由 Gravitas Capital LP 和养老金计划持有的股份。</p>
</div><p>Original SEC Filing: Hepion Pharmaceuticals, Inc. [ HEPA ] - SCHEDULE 13D - May. 01, 2026
<strong>Disclaimer</strong></p>
<div class="lb-trans"><p>原始 SEC 文件: Hepion Pharmaceuticals, Inc. [ HEPA ] - SCHEDULE 13D -2026 年 5 月 1 日
<strong>免责声明</strong></p>
</div><p>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</p>
<div class="lb-trans"><p>这是一个由人工智能生成的摘要，可能包含不准确之处。请考虑与来源核实重要信息。请注意，此摘要仅基于提交给 SEC 的文件。</p>
</div>

Vincent LoPriore Discloses Investment at Hepion Pharmaceuticals with 21.46% Stake

TradingView

Hepion Pharmaceuticals

Vincent LoPriore 披露在 Hepion Pharmaceuticals 持有 21.46% 的股权